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Abstract 
In August 2018, CVS Health released a position paper detailing policies in place and those being implemented to help reduce the costs 
of drugs. This paper introduced three new strategies for reducing costs. These are (i) zero out of pocket costs for chronic disease through 
a preventive drug list; (ii) reducing the launch price through adoption of modeled cost-per-QALY outcomes by the Institute for Clinical 
and Economic Review (ICER) to guide clients to exclude drugs launched at a price of greater than $100,000 per QALY; and (iii) 
introducing tools to be used by doctors, pharmacists and consumers to create greater transparency in understanding the real cost of 
drugs. The purpose of this commentary is to consider the second of these strategies, the application of a willingness to pay threshold 
as a viable strategy for impacting launch costs. The arguments presented here are that while modeled cost-per-QALY claims are a 
staple of formulary committee deliberations in many single payer health systems, their adoption by CVS Health fails to take into account 
not only the imaginary nature of the modeled construct utilized to generate the cost-per-QALY estimate and its shortcomings but the 
fact that alternative model structures may render invalid the application of willingness-to-pay thresholds. The case is made that CVS 
Health could adopt a more rigorous process of formulary assessment to support both preliminary assessments of new products and 
also an ongoing process of formulary review that challenge manufacturers to justify pricing over product patent life. This process should 
capitalize on the development of formulary evaluation platforms, potentially involving blockchain technology and smart contracting, 
for therapy interventions in targeted patient populations. Introducing a more rigorous formulary process, in particular the requirement 
for claims evaluation protocols, will not only assist CVS Health in restraining price increases over the life of the product but, for the first 
time in the US, put manufacturers on notice that patently unreasonable pricing policies and claims for product performance can be 
systematically and effectively challenged.  
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Introduction 
Over the past 2 years a number of commentaries have 
appeared in INNOVATIONS in Pharmacy that have made the 
case (i) that modeled claims for cost-effectiveness, notably 
those that rely on lifetime cost-per-quality adjusted life year 
(QALY)  estimates lack scientific merit and (ii) that claims for 
cost-effectiveness and pricing recommendations based on 
willingness-to-pay thresholds put forward by the Institute for 
Clinical and Economic Review (ICER) should be put to one side 
in favor of the evaluation of modeled claims that are credible, 
evaluable and replicable1,2. Unfortunately, this message has    
yet to resonate fully with formulary committees and 
pharmaceutical manufacturers. Among the former would 
appear to be CVS Health in their latest announcement that  as 
one of the tools at their disposal for reducing overall medical 
costs, notably the cost of pharmaceuticals,  they propose to 
introduce the rule that allows their clients ‘to exclude any drug 
launched at a price of greater than $100,000 per QALY from 
their plan’3. The choice of product will be based on ‘publicly 
available analyses’ from the ICER. 
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While CVS Health believes that the implementation of a 
$100,000 willingness-to-pay cutoff will be a significant addition 
to their armamentarium, this belief rests on an assumption that 
lifetime cost-per-QALY claims or similar ICER models have 
scientific merit. This presumption is far from the case. ICER and 
similar models lack scientific credibility because the claims 
made, whether they are for comparative clinical effectiveness 
or cost-effectiveness are not credible4.  
 
The purpose of this commentary is to point to: (i) the limitations 
of the ICER modeling framework; (ii) the implications of CVS 
Health factoring in ICER modeled claims with cost-per-QALY 
thresholds into formulary decisions; and (iii) the need for 
guidelines for formulary evaluation that have the potential to 
provide, not only a robust evidence base for evaluating claims 
but one that can extend over the patent life of products.  
 
Policies Towards Drug Price Inflation 
CVS Health has implemented a number of policies directed 
towards containing drug prices and costs. CVS Health claims 
that these initiatives have had a positive and significant impact 
on adherence and overall health costs3. These initiatives are: (i) 
encouraging the greater use of generics; (ii) application of prior 
authorizations for effective use; and (iii) strategies to obtain 
rebates and discounts from manufacturers. Most recently, 
three further initiatives have been detailed. These are: (i) a 
preventive drug list for zero out-of-pocket costs for chronic 
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disease; (ii) reducing the launch price through comparative 
effectiveness exclusions; and (iii) the introduction of tools to 
ensure greater transparency to encourage doctors, pharmacists 
and consumers to engage in cost control. 
 
Consider the second of these recent initiatives: the program to 
exclude drugs launched at a price greater than $100,000 per 
QALY from a client’s plan. This program rests on the application 
of ICER modeled claims for cost-effectiveness. If ICER has 
concluded that, based upon its modeling framework, a ‘me to’ 
medication is not cost-effective then the CVS Health program 
will allow clients to exclude that drug from their plan. This 
potential for exclusion is a seen as a  red flag for manufacturers 
proposing a launch price that generates an ICER modeled cost-
per QALY greater than a willingness-to-pay of $100,000 per 
QALY. Whether this policy is sustainable is another question. 
 
The ICER Modeling Framework 
The ICER modeling framework has been reviewed in a number 
of earlier commentaries. Briefly, it is a US version of the 
National Institute for Health and Care Excellence (NICE) lifetime 
cost-per-QALY reference case model, versions of which have 
been introduced by other single payer health systems such as 
Australia, Canada, Ireland and New Zealand5,6,7,8,9. The 
reference case in the UK mandates that all submissions for new 
products must be presented, with few exceptions, within a 
constructed lifetime cost-per-QALY framework. The model is 
‘for information only’ and not, as clearly stated in the latest 
Canadian guidelines, intended to conform to the standards of 
normal science:  Economic evaluation are designed to inform 
decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses10,11. In short, 
we should base formulary decisions on ‘information’ created 
from imaginary constructs. We are asked to accept that the 
construct, which often extends decades into the future, is 
‘informative’ because its structure and assumptions are 
‘reasonable’ and ‘realistic’. The fact that it is entirely possible, 
and probably a necessary marketing counterpoint, to build 
competing ‘informative’ models is, presumably, beside the 
point.  
 
One reason for building a lifetime model is that it supports the 
application of willingness to pay thresholds. Outcomes are 
expressed as ‘all embracing’ QALYS to capture morbidity and 
mortality with assumptions as to lifetime direct medical costs. 
Drug costs are at the discretion of the manufacturer or a model 
builder such as ICER, although interestingly enough, ICER makes 
no assumptions as to how drug prices are expected to increase 
over the patent lifetime. If they did, modeled costs would be 
substantially inflated.  
 
Once lifetime QALYs and costs are calibrated, these are 
expressed as lifetime cost-per-QALYs and matched to 
thresholds. The favorite thresholds are $50,000, $100,000 and 
$150,000 per QALY. ICER uses these thresholds to support 
pricing recommendations. Obviously, if a manufacturer is 
preparing a reference case submission, their constructed 
imaginary world can either be designed to support a base 
pricing point as part of a long-term incremental pricing strategy 
or it can be used as a framework for reviewing alternative 
pricing options. They could even argue for imaginary cost-per-
QALY sliding scales in $10,000 increments depending on the 
disease state. Indeed, a cynical reviewer might add that a model 
can support a ‘bait and switch’ pricing strategy where a 
deliberately low base price is chosen to ensure that an 
acceptable threshold is met. Once an acceptable formulary 
position is agreed, which might even involve short-term 
discounting to smooth product acceptance; this can then be 
followed within a matter of months by a succession of 
incremental price increases.  
 
Consider as an example a new drug which has a proposed 
annual cost of $20,000 at market entry. A succession of annual 
price increases of 8% means that in 15 years the cost will have 
risen to $54,200 with further increases until it loses patent 
protection or is replaced. The fact that manufacturers can 
exploit their position as a monopolist to extract substantial and 
increasing rents over the lifetime of a product means that 
claims that a product is cost-effective are meaningless. The 
$100,000 per QALY willingness-to-pay threshold has no 
relevance. Different imaginary models will generate different 
claims.   
 
Previous commentaries have addressed the model 
shortcomings of a number if ICER product reviews12,13,14,15. All 
have pointed to the often limited basis for modeled 
assumptions in terms of not only the clinical claims but the 
translation of these into QALYs. Further limitations noted have 
been assumptions (or their absence) regarding patterns of 
adherence and compliance together with, as noted above, 
assumptions as to the anticipated lifetime pricing of drugs and 
other direct medical costs. Pointing to these limitations only 
goes to emphasize the basic weakness of any ‘for information’ 
lifetime or long-term modeled claim: it can always be 
challenged with competing models constructed to come to 
different conclusions on what may appear to be quite 
reasonable and well-argued assumptions. 
 
Consider as an example two models. One model, where a target 
cohort of patients is modeled over their projected lifetimes and 
which takes account of adherence and persistence with 
therapy. If compliance is only short term with, say, 50% of 
patients initiated to a therapy for a chronic disease 
discontinuing therapy within two years, then cost-per- QALY 
claims will apply only to the cumulative and diminishing 
number of patients assumed to remain on therapy. The 
competing model, rather than considering just an initial cohort 
of patients modeled over their lifetimes might take the 
perspective of patients being recruited by the manufacturer to 
offset those lost to treatment as well as capturing increased 
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market share for a fixed projection period. Over the timeframe 
of the model new patients will enter each year who will then 
begin to discontinue therapy. The profile of QALYs will be quite 
different. If QALYs are time dependent, then the overall QALY 
profile will be the sum of the QALYs experienced in that year 
across the cohorts of patients initiated to therapy in each year. 
Cost-per-QALY claims and the aggregate QALY and cost profile 
will be different between the two models. Claims for the first 
model will rest on the outcomes for a modeled cohort of 
patients initiated to therapy while the second is based on the 
assumption of a constant or growing cohort of patients with 
those discontinuing being continuously replaced over the 
lifetime of the product. 
 
It is also worth noting that there is an ongoing debate over the 
transparency of the ICER modeling approach and the scope 
given to manufacturers to challenge the model in the early 
stages of its development by groups contracted to ICER16. A key 
point of contention is early access to the actual model that 
would allow manufacturers to challenge the model structure 
and modify or replace assumptions. While this may appear a 
somewhat fruitless exercise as the net result could be an 
‘imaginary worlds challenge cup’ (which has been a feature of 
diabetes modeling) the bottom line is that it serves as a 
smokescreen17. As formulary review groups would typically not 
have the skills to evaluate the technical and evidence-based 
attributes of competing models, the result may simply be to put 
the models to one side in favor of more direct negotiations.  
 
Abandoning ICER for PROST 
If the ICER approach to pricing recommendations is seen as a 
dead-end, is there an alternative to the construction of 
imaginary cost-per-QALY worlds and willingness-to-pay 
thresholds? The answer is ‘yes’ once we put aside the ‘need’ for 
reference cases and focus on the evidence base necessary for 
initial and ongoing disease area and therapeutic class reviews 
by formulary committees.  
 
A manufacturer cannot expect a formulary decision to accept a 
product at a base price and tier position to be unchallenged 
over the patent life of the product. A manufacturer should 
recognize that in the case of both an initial formulary decision 
and future disease area and therapeutic class reviews, it must 
assure the formulary committee that the claims made initially 
in respect of comparative clinical benefits are not only credible, 
evaluable and replicable but that these should continue to be 
addressed over the patent life. The focus must switch from 
pseudoscientific constructed ‘information’ paradigm to one in 
which ‘evidence’ drives decisions.  
 
The theme that product claims, which would include both 
extrapolated and modeled claims, should be credible is 
addressed in the proposed Minnesota guidelines for formulary 
evaluations. Version 2.0 of these guidelines released in 
December 2016 are focused on the evidentiary standards 
required to support initial informed drug choice18,19. Following 
from the standards established in randomized controlled trials, 
the proposal is that formulary submissions be accompanied by 
a study protocol (the PROST protocol) detailing how the claims 
for clinical outcomes, cost-effectiveness and budget impact are 
to be evaluated. This evaluation process is relevant both for 
new products seeking formulary approval as well as for ongoing 
disease area and therapeutic class reviews. The protocol is 
intended to support a short-term assessment of claims made 
with feedback to the formulary committee within a meaningful 
timeframe. Until those results are available any initial decision 
on pricing and tier position (including prior-authorization) 
should be considered provisional. It is proposed that until 
claims are verified a low provisional price would be agreed. 
Indeed, even after a final price is agreed following validation, 
which may be 12 to 20 month later, it is suggested that the 
manufacturer agree to a fixed price unless a price increase can 
be justified. 
  
This emphasis on evaluation and replication reflects, as noted 
above, the limited evidence base supporting all too many 
clinical claims and the apparent difficulties that independent 
assessors have had in replicating phase 3 protocol based claims. 
Claims which are, all too frequently, captured by ICER-type 
models with no thought given to undertaking an in-house 
assessment to replicate those claims in the target patient 
population before launching into construction of an imaginary 
world.   
 
A PROST Platform 
There are a number of options open to manufacturers 
submitting a protocol for claims assessment in the choice of 
platform. Clearly, two of the key requirements for a PROST 
platform are that they allow physicians and patients to engage 
with each other and that there is feedback in real time to 
monitor response to therapy. Other required features, and this 
will be likely a prospective observational study design, are to 
ensure randomization within the target population and then 
ensure that the power of the study can overcome the lack of 
power of for secondary endpoints that typically characterize 
RCTs. The fact that underpowered secondary endpoints 
(including QALYs) are used as the basis for lifetime modeled 
claim assumptions needs to be addressed. In practical terms, 
there should be at least a sub-group within those selected to 
capture the inclusion/exclusion criteria established in the key 
phase 3 RCTs. To minimize delays in formulary agreement with 
the manufacturer on a protocol, the draft protocol, to include 
the proposed evidence platform should be, as outlined in the 
PROST framework, part of the formulary submission. 
 
One option for the platform is a target population registry. 
While this is feasible, a more attractive option would be a 
blockchain20. The blockchain has three advantages: first, it is a 
secure, encrypted and portable transaction ledger; second, it 
can support medical records which can be linked to any number 
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of registries held by the blockchain for initial and ongoing 
formulary evaluations; and third, it can support incentivized 
smart contracting by patients to monetize their health data. 
These aspects of a blockchain as a medical record to support 
health technology assessments including formulary evaluations 
have been explored in recent commentaries21,22. The overriding 
consideration, however, is that the ability to construct lifetime 
health record blockchains puts to one side reliance on driving 
formulary decisions through the construction of imaginary 
worlds; an unfortunate attribute of health technology 
assessment for the past 30 years.    
 
Conclusions 
If CVS Health wishes to factor into their formulary decision-
making claims for cost-per-QALY outcomes based on the 
construction of imaginary worlds, they are entitled to do so. 
However, in embracing the ICER approach the concern is that 
few people, including probably those making decisions within 
CVS Health, will have the skills to recognize the 
inappropriateness and insubstantial nature of the ICER 
methodology. Taking ICER claims at face value is accepting a 
black box. If there is one thing we have learned from countries 
that have a transparent (UK) or pseudo-transparent (Australia) 
modeling assessment process, is the obvious fact that any 
model can be constructed or re-engineered to support a range 
of pricing and outcomes assumptions. If we add to this another 
obvious fact that expressing outcomes over the lifetime of the 
patient population or the natural course of the disease asks the 
reader to accept that we have a crystal ball that enables us to 
create a realistic world stretching decades into the future with 
QALYs and costs accumulating over that timeframe. We are 
asked to accept the credibility of these claims, or rather the 
assumptions supporting these claims when we know they were 
never intended to be subjected to the evidentiary standards of 
normal science. In fact, they are designed to do exactly the 
opposite. This reduces to a debate over visions of the future. 
 
To end on a more positive note; with resources available it 
would surely not be beyond the bounds of possibility for CVS 
Health to support a commitment to the scientific method in 
funding a health technology assessment group for assessing 
claims with competing pharmaceutical products. Certainly, 
such a commitment would mean rejecting imaginary constructs 
in favor of an evidence or outcomes based formulary. After all, 
denying coverage (i.e., access) to a drug on the basis of an 
imaginary lifetime cost-per QALY black-box construct may not 
sit well with the CVS Health client base. Not only would 
exclusion decisions lack scientific credibility but they open the 
door, not only to challenges from manufacturers and their 
lobby groups with their own re-engineered models, but to 
likelihood of challenges also from patients, providers and their 
associations.  At the same time, as emphasized above, 
establishing a technology assessment group would not only act 
as gatekeeper for new products but would be in a position for 
CVS Health monitor and challenge arbitrary pricing strategies 
over the lifetime of the product.  
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